Silexion Therapeutics (SLXN) Assets Average (2024 - 2026)

Silexion Therapeutics' Assets Average history runs 3 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• In Q1 2026, Assets Average rose 5.78% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (up 5.78% YoY), while the FY2025 annual figure was $5.0 million, up 24.13% from the prior year.
• Assets Average for Q1 2026 stood at $5.9 million, down from $9.4 million in the prior quarter.
• The five-year high for Assets Average was $9.4 million in Q4 2025, with the low at $2.7 million in Q3 2024.
• The 3-year median for Assets Average is $5.6 million (2025), against an average of $5.5 million.
• The sharpest annual moves came in 2025 and 2026: Assets Average surged 222.31% in 2025, then gained 5.78% in 2026.
• Silexion Therapeutics' Assets Average stood at $3.0 million in 2024, then surged by 216.45% to $9.4 million in 2025, then tumbled by 37.24% to $5.9 million in 2026.
• Business Quant data shows SLXN's Assets Average at $5.9 million in Q1 2026, $9.4 million in Q4 2025, and $8.7 million in Q3 2025.